[go: up one dir, main page]

WO2003035093A1 - Composition antibacterienne contenant des extraits de plantes - Google Patents

Composition antibacterienne contenant des extraits de plantes Download PDF

Info

Publication number
WO2003035093A1
WO2003035093A1 PCT/KR2002/000826 KR0200826W WO03035093A1 WO 2003035093 A1 WO2003035093 A1 WO 2003035093A1 KR 0200826 W KR0200826 W KR 0200826W WO 03035093 A1 WO03035093 A1 WO 03035093A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
antibacterial
antibacterial composition
trichophyton
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2002/000826
Other languages
English (en)
Inventor
Haeng-Byoung Lee
Soon-Il Kim
Byeong-Mook Park
Young-Jun Ahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naturobiotech Co Ltd
Original Assignee
Naturobiotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020010065813A external-priority patent/KR20020008809A/ko
Application filed by Naturobiotech Co Ltd filed Critical Naturobiotech Co Ltd
Publication of WO2003035093A1 publication Critical patent/WO2003035093A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/235—Foeniculum (fennel)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/268—Asarum (wild ginger)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus

Definitions

  • the present invention relates to an antibacterial composition
  • Skin diseases caused by fungi are generically called dermatomycosis. Particularly, those caused by a dermatophyte that invades corneous tissues
  • dermatophytosis such as keratin, hair, fingernails, toenails, etc. and are parasitic thereon are called dermatophytosis, Tinea, or superficial fungal infection (Ribbon, J. W.
  • Tinea manus & Tinea pedis for hand and foot
  • Tinea faciale for face Tinea crusis for the groin
  • Tinea capitis Tinea capitis for the head
  • Microsporum Major causes for superficial fungal infection are Microsporum,
  • Microsporum mainly invades skin and hair; epidermophyton invades skin and
  • Candida causes disease on skin and mucous membranes
  • Malassezia furfur causes tinea versicolor, which causes spots.
  • Pathogenic fungi do not always cause disease by contact, and whether or not infection occurs therewith depends on the kinds of
  • keratin layer and some species invade and inhabit animal tissue. For convenience, they are divided into Anthrophillic (parasitic on humans),
  • a keratin-solvent is
  • the present invention provides an
  • antibacterial composition comprising an extract of one or more kinds of plants
  • the present invention also provides an antibacterial composition
  • Fig. 1 shows a process for separating eugenol from a methanol extract
  • Fig. 2 shows a process for separating eugenol and isoeugenol from
  • Foeniculum vulgare is known to have almost the same major
  • Cinnamomum sp. plants include Cinnamomum sieboldii, C. cassia, C.
  • C. cassia belonging to the Lauraceae family, and when dried are called C. cassia or
  • Cinnamomum sieboldii Cinnamomum sieboldii.
  • cloves The scientifical name of cloves is Eugenia caryophyllata or Syzygium aromaticum, and the essential oil therefrom is commonly used as clove bud or leaf oil.
  • clove bud oil is a plant oil obtained only from the buds of
  • the plant extract of the present invention is prepared by a common extraction method, preferably by mixing the pulverized plant with distilled water, alcohol, or organic solvent; fractioning the mixture; and removing the solvent.
  • the alcohol is preferably C1-5; more preferably ethanol, methanol, propanol, or
  • butanol and most preferably methanol.
  • the organic solvent is preferably
  • the extraction region is the flower, branch, trunk, bud, root, bark, fruit, seed, plant
  • Foeniculum vulgare extract is preferably from its fruit, Asarum
  • heterotropoides extract is preferably from its root, and Cinnamomum sp. plants
  • plants of the present invention can be made into
  • Plant essential oil is extracted by common essential oil
  • extraction methods include distillation and expression using water or vapor.
  • Marketed essential oil includes fennel sweet oil (Foeniculum vulgare oil),
  • Cinnamon oil (C. cassia oil), and clove bud oil (clove oil).
  • the present invention provides a plant-derived anti-fungal compound.
  • the anti-fungal compound includes clove-derived compounds
  • the anti-fungal compounds can be purchased as marketed compounds, or they can be separated and purified
  • the present invention also provides an antibacterial composition
  • composition has growth-inhibition activity for pathogenic fungi, and it preferably
  • the anti-fungal composition of the present invention has antibacterial effects for pathogenic fungi as shown in Table 1. Representative pathogenic fungi
  • fungi include Trichophyton rubrum, KCTC 6345; Microsporum audouinii, KCTC
  • KCTC 6586 Trichophyton mentagrophytes
  • KCTC 6077 Trichophyton mentagrophytes
  • Candida albicans Trichophyton mentagrophytes
  • the anti-fungal composition of the present invention can be used for treating and/or inhibiting
  • plasters preferably plasters, granules, lotions, liniments, limonades,
  • cataplasma capsules, creams, troches, tinctures, pastes, or pills.
  • the anti-fungal composition may further comprise pharmaceutically acceptable vehicles according to its preparation and use method, and the
  • contents of plant extracts or essential oils in the composition are preferably 1 to 20 wt%.
  • a dose of the composition is preferably 10 to 50 mg and the frequency is preferably one to three times per day, but it is preferably controlled according to the degree of disease and health condition of the patient.
  • Cinnamomum sieboldii or Eugenia caryophyllata, and C. cassia were used as Cinnamomum sieboldii or Eugenia caryophyllata, and C. cassia were used as Cinnamomum sieboldii or Eugenia caryophyllata, and C. cassia were used as Cinnamomum sieboldii or Eugenia caryophyllata, and C. cassia were
  • methanol extracts were prepared by the same method, and methanol
  • Foeniculum vulgare oil, Cinnamomum sieboldii oil, C. cassia oil, and clove oil were purchased from Jin-a Perfume Inc.
  • the essential oils were prepared by steam distillation, as follows.. A
  • the amount of sample required for one distillation was 250 g, and after
  • KCTC 7728 were obtained from the Korean Collection for Type Cultures, KCTC. Growth-inhibition activities were
  • strains were inoculated on a Sabouraud's agar medium, and each
  • methanol extract from Example 1 was dissolved in methanol and applied to a paper disc or each essential oil (from Example 2) was directly applied to a paper disc.
  • the paper discs were mounted on each of the mediums
  • the fungi were aerobically cultured for 5 days
  • Table 2 shows growth-inhibition activities of the 5 species of bacteria causing Trichophytia and 1 species of Candida caused by the methanol
  • Cinnamomum sieboldii methanol extract and oil formed very strong clear zones when 10 mg and 50
  • the hexane fraction showed antibacterial activity.
  • H1 (1 .4 g), H2 (27 g), H3 (0.4 g), and H4
  • Isoeugenol and eugenol were separated from 1 mg of clove oil (Fig. 2).
  • H1 , H2, and H3 were purified using a fractioning column ( ⁇ Porasil, resin
  • H2 and H3 were confirmed to have antibacterial activities.
  • H2 was identified as eugenol
  • H3 isoeugenol
  • Isoeugenol is represented by the Chemical Formula 2.
  • clotrimazole is a positive control.
  • audouinii audouinii
  • fenchone showed very strong inhibition activity when 50 mg per
  • Cinnamic aldehyde and methyleugenol were applied. Cinnamic aldehyde and methyleugenol showed
  • Foeniculum vulgare oil was dissolved in ethanol to prepare a 5%
  • the Foeniculum vulgare oil composition was sprayed on the subjects'
  • Keratin formation was very conspicuous, and athlete's foot
  • Foeniculum vulgare oil composition causes keratinization
  • antibacterial extracts were obtained by: According to the present invention, antibacterial extracts were obtained by:
  • the antibacterial extracts and compounds can be used as natural antibacterial compounds without toxicity because they have

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention se rapporte à une composition antibactérienne contenant des extraits de plantes, et plus particulièrement, un extrait de une ou plusieurs sortes de plantes choisies dans un groupe comprenant les plantes Foeniculum vulgare, Illicium verum, Asarum heterotropoides, Cinnamomum, des gousses, et un composé antibactérien fabriqué à partir de ces éléments.
PCT/KR2002/000826 2001-10-24 2002-05-03 Composition antibacterienne contenant des extraits de plantes Ceased WO2003035093A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR2001/0065813 2001-10-24
KR1020010065813A KR20020008809A (ko) 2001-10-24 2001-10-24 식물 추출물을 포함하는 항균제 조성물
KR2002/0003839 2002-01-23
KR1020020003839A KR100371858B1 (en) 2001-10-24 2002-01-23 Antimicrobial composition containing plant extract

Publications (1)

Publication Number Publication Date
WO2003035093A1 true WO2003035093A1 (fr) 2003-05-01

Family

ID=26639423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2002/000826 Ceased WO2003035093A1 (fr) 2001-10-24 2002-05-03 Composition antibacterienne contenant des extraits de plantes

Country Status (1)

Country Link
WO (1) WO2003035093A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532124B2 (en) 2012-12-27 2020-01-14 Kimberly-Clark Worldwide, Inc. Water soluble farnesol analogs and their use
US10717946B2 (en) 2012-12-27 2020-07-21 Kimberly-Clark Worldside, Inc. Water soluble essential oils and their use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612086A1 (de) * 1986-04-10 1987-10-15 Bayer Ag Konservierte antacida-zubereitungen
JPH045237A (ja) * 1990-04-24 1992-01-09 Nonogawa Shoji Kk スーパーオキシド消去剤
JPH04278069A (ja) * 1991-02-28 1992-10-02 Shokuhin Sangyo Chokoatsu Riyou Gijutsu Kenkyu Kumiai 静菌剤
JPH07196522A (ja) * 1993-12-28 1995-08-01 Rohto Pharmaceut Co Ltd 抗ヘリコバクター・ピロリ活性剤
US5486537A (en) * 1995-01-20 1996-01-23 Dayton Laboratories, Inc. Topical anti-fungal composition for skin and keratinous tissue
WO1998040086A2 (fr) * 1997-03-10 1998-09-17 The Riley Fletcher Foundation Composition d'huile essentielle
JPH11315029A (ja) * 1998-04-30 1999-11-16 Sunstar Inc 薬用植物の処理方法およびそれにより得られた処理物および該処理物を配合した液体組成物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612086A1 (de) * 1986-04-10 1987-10-15 Bayer Ag Konservierte antacida-zubereitungen
JPH045237A (ja) * 1990-04-24 1992-01-09 Nonogawa Shoji Kk スーパーオキシド消去剤
JPH04278069A (ja) * 1991-02-28 1992-10-02 Shokuhin Sangyo Chokoatsu Riyou Gijutsu Kenkyu Kumiai 静菌剤
JPH07196522A (ja) * 1993-12-28 1995-08-01 Rohto Pharmaceut Co Ltd 抗ヘリコバクター・ピロリ活性剤
US5486537A (en) * 1995-01-20 1996-01-23 Dayton Laboratories, Inc. Topical anti-fungal composition for skin and keratinous tissue
WO1998040086A2 (fr) * 1997-03-10 1998-09-17 The Riley Fletcher Foundation Composition d'huile essentielle
JPH11315029A (ja) * 1998-04-30 1999-11-16 Sunstar Inc 薬用植物の処理方法およびそれにより得られた処理物および該処理物を配合した液体組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199230, Derwent World Patents Index; AN 1992-060692 *
DATABASE WPI Week 199539, Derwent World Patents Index; AN 1995-299502 *
DATABASE WPI Week 200005, Derwent World Patents Index; AN 2000-058155 *
PATENT ABSTRACTS OF JAPAN *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532124B2 (en) 2012-12-27 2020-01-14 Kimberly-Clark Worldwide, Inc. Water soluble farnesol analogs and their use
US10717946B2 (en) 2012-12-27 2020-07-21 Kimberly-Clark Worldside, Inc. Water soluble essential oils and their use
US11383003B2 (en) 2012-12-27 2022-07-12 Kimberly-Clark Worldwide, Inc. Water soluble farnesol analogs and their use

Similar Documents

Publication Publication Date Title
CN101375933B (zh) 制备用于治疗皮肤病症和促进伤口愈合的植物提取物的方法
Pandey et al. Essential oil compositions, pharmacological importance and agro technological practices of Patchouli (Pogostemon cablin Benth.): A review
US9572849B2 (en) Recovery of residual plant components after distillation of essential oils
JP2010506899A (ja) Ｃｉｎｎａｍｏｍｉ（ケイシ）及びＰｏｒｉａ（ブクリョウ）組成物及びその利用法
JP2004537578A (ja) アーティチョーク葉抽出物
KR20020008809A (ko) 식물 추출물을 포함하는 항균제 조성물
Shinkafi Phytochemical analysis and chromatographic studies of Pergularia tomentosa L. and Mitracarpus scaber Zucc.
CN113713003B (zh) 一种艾叶提取物及其制备方法与应用
KR100387939B1 (ko) 식물 추출물을 포함하는 항균제 조성물
WO2003035093A1 (fr) Composition antibacterienne contenant des extraits de plantes
KR100427584B1 (ko) 식물 추출물을 포함하는 항균제 조성물
Jimoh et al. Phytochemical and Gas Chromatography-Mass Spectrometry (GC-MS) Analysis of Ethyl Acetate Root Extract of Indigofera Diphylla
Famurewa GC-MS Based Metabolite Profiling and Phytochemical Screening of Different Solvent Extracts of Moringa oleifera Seeds
KR100437576B1 (ko) 신나밀알콜을 포함하는 항진균제 조성물
PT117531B (pt) Produto com componentes de eucalyptus globulus para uso como antifúngico, como anti-inflamatório e anti-senescente para aplicação tópica na ausência de citotoxicidade
Abdullahi et al. Biological investigation and chemical constituents of Croton nigritanus scott Elliot
Rehman et al. An overview of the pharmacological properties and potential applications of lavender and cumin
Kumar et al. Physicochemical properties, GC-MS analysis and impact of different material size on yield of Himalayan C. deodara essential oil
Aiwonegbe et al. Antiulcerogenic activity of methanol extract from Ipomoea asarifolia leaves in Wistar rats
KR100649121B1 (ko) 배초향 정유 및 케토코나졸을 유효성분으로 함유하는 복합항진균제
Mokaizh et al. Phytochemical and pharmacological activities of Commiphora gileadensis: A review
Al-Yasiri et al. Study the Effecte of Oreganum Vulgare L. Extratct Against Some Pathogenic Fungi
Mary et al. Bioprofiling of Polyherbal Mixture Towards Plant-Derived Pharmaceuticals
AU2008300612C1 (en) Production of leaf extracts of Pittosporum phillyraeoides and the use thereof in medicine
Rita et al. The toxic compounds from citrus parasite (Scurrula ferruginea (Jack) Danser.)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP